MET and non-small cell lung carcinoma: Importantly, clinical studies have shown that a subset of NSCLC patients with concomitant c-MET and SYK overexpression demonstrated a notably high response rate of 73.3% and longer PFS when treated with c-MET inhibitors compared to other patient subgroups.